Ongoing Clinical Trials for Choroidal Neovascularisation
There are currently 2 clinical trials underway investigating new treatments for choroidal neovascularisation and related eye conditions. These trials are being conducted in Poland and Latvia, testing medications delivered through eye injections to help manage abnormal blood vessel growth in the eye that can lead to vision loss.
Clinical trial locations
- Latvia
- Poland
Study on the Use of SB11 Pre-Filled Syringe for Patients with Wet Age-Related Macular Degeneration, Macular Edema from Retinal Vein Occlusion, or Myopic Choroidal Neovascularization
This trial is taking place in Poland and focuses on evaluating a new delivery method for an eye medication called Byooviz, which contains ranibizumab. The study aims to assess how easily healthcare professionals can use a pre-filled syringe to inject this medication directly into the eye.
Who can participate:
- Adults aged 18 years or older
- People diagnosed with neovascular age-related macular degeneration, macular swelling due to retinal vein blockage, or myopic choroidal neovascularization in the eye being studied
- Individuals whose condition is suitable for treatment with ranibizumab injections, as determined by an eye specialist
- Those willing to attend all scheduled visits and assessments
- Women who cannot become pregnant or who are past menopause, or individuals willing to use effective birth control for three months after the injection
Who cannot participate:
- People with other eye diseases that could affect the study results
- Those who have had eye surgery in the past three months
- Individuals currently receiving or who have received other eye treatments within the past three months
- People with a history of severe allergic reactions to the study medications
- Those with uncontrolled high blood pressure or serious health conditions
- Women who are pregnant or breastfeeding
- People participating in another clinical trial
What the trial involves: The study is designed to evaluate how well healthcare professionals can follow instructions to prepare and administer the pre-filled syringe containing SB11. Participants will receive a single injection directly into the eye and will be monitored for one week afterward to check for any side effects or changes in vision. The medication being tested, SB11, is an anti-VEGF agent that works by targeting proteins in the eye that contribute to abnormal blood vessel growth and leakage, helping to reduce swelling and potentially improve vision.
Study on the Safety and Use of AVT06 (Aflibercept) for Patients with Chorioretinal Vascular Diseases
This trial is being conducted in Latvia and examines the handling and safety of a medication called Aflibercept (AVT06) for treating various eye conditions related to blood vessel problems in the retina. The study focuses on ensuring that the pre-filled syringe version of this medication can be administered safely and correctly.
Who can participate:
- Adults aged 18 years or older
- People diagnosed with one of the following conditions: neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, diabetic retinopathy, or myopic choroidal neovascularization
- Individuals whose condition is suitable for treatment with aflibercept, as determined by the study doctor
- Those able to read, understand, and sign the consent form
- People willing to follow all study procedures and likely to complete the study
- Males and females who agree to use contraception during treatment and for at least three months after the last injection
Who cannot participate:
- People with other eye diseases not related to blood vessel problems
- Those who have recently had eye surgery or are planning to have eye surgery during the study
- Individuals with an eye infection or inflammation at the time of the study
- People allergic to the study medications or their ingredients
- Those participating in another clinical trial at the same time
- Individuals with serious illnesses that might affect their ability to participate
- Women who are pregnant or breastfeeding
- People with a history of drug or alcohol abuse
- Those unable to follow study instructions or attend required visits
What the trial involves: The study assesses how well the pre-filled syringe can be handled and evaluates the safety of the medication when injected into the eye. Participants will receive an injection of aflibercept directly into the eye and will be monitored for four weeks to check for any side effects. The trial also includes an optional extension phase for further observation. AVT06 is an anti-angiogenic agent that works by targeting specific pathways involved in abnormal blood vessel growth and leakage in the retina, helping to reduce vision loss.
Summary
Both trials focus on evaluating the safety and usability of pre-filled syringes for delivering medications directly into the eye to treat conditions involving abnormal blood vessel growth. The trials are being conducted in different countries, with one in Poland testing SB11 (ranibizumab) and another in Latvia testing AVT06 (aflibercept). Both medications belong to the anti-VEGF class of drugs, which help reduce abnormal blood vessel growth and leakage in the eye. These studies are particularly important for understanding how these new delivery methods can make treatment easier for healthcare professionals while maintaining safety and effectiveness for patients with vision-threatening eye conditions.